ReviewJournal of the European Academy of Dermatology and Venereology : JEADV2025
Bullous pemphigoid burden of disease, management and unmet therapeutic needs.
Review in Journal of the European Academy of Dermatology and Venereology : JEADV, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients.Dermatology (Basel, Switzerland) · 2026Article
- Corticosteroid-Sparing Control of Bullous Pemphigoid with Dupilumab and Tripterygium Glycosides: A Real-World Cohort with Longitudinal Transcriptomics.Journal of inflammation research · 2026Article
- Thematic Evolution and Diversification of Bullous Pemphigoid Research: A Bibliometric Analysis, 1959-2025.Clinical, cosmetic and investigational dermatology · 2026Article
- Omalizumab in the management of bullous pemphigoid: a six-month retrospective study.Postepy dermatologii i alergologii · 2026Article
- Bullous pemphigoid burden of disease, management and unmet therapeutic needs.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Bullous pemphigoid: Investigating the risk of losing functional autonomy in everyday life.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Article
- Dupilumab-Induced Systemic Hypoperfusion in an Elderly Patient: A Case Report.Journal of inflammation research · 2025Article
- Increased risk of atrial fibrillation among patients with bullous pemphigoid: a nationwide cohort study in Taiwan.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bullous pemphigoid (BP) is an autoimmune blistering disease that can have a profound negative impact on quality of life. BP most often affects the elderly, a population with a high medical burden and special safety concerns. In this review, we outline the BP disease course, diagnosis, epidemiology and comorbidities, and describe tools commonly used to assess BP disease activity and severity and the impact of BP on health-related quality of life. We also outline biologic treatments currently under investigation for the treatment of BP and highlight the importance of considering safety when treating elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.